(Q37767397)

22 August 2017

1 reference

title

A review of low-dose-rate prostate brachytherapy--techniques and outcomes (English)

1 reference

22 August 2017

1 reference

David M Marcus

1

1 reference

22 August 2017

Ashesh B Jani

series ordinal

2

1 reference

22 August 2017

Karen Godette

series ordinal

3

1 reference

22 August 2017

Peter J Rossi

series ordinal

4

1 reference

22 August 2017

publication date

1 June 2010

1 reference

Journal of the National Medical Association

22 August 2017

published in

1 reference

22 August 2017

volume

102

1 reference

22 August 2017

issue

6

1 reference

22 August 2017

page(s)

500-510

1 reference

22 August 2017

cites work

Cancer statistics, 2008

1 reference

https://api.crossref.org/works/10.1016%2FS0027-9684%2815%2930559-9

Dawn of prostate brachytherapy: 1915-1930.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0027-9684%2815%2930559-9

Brachytherapy in cancer of the prostate: an historical perspective

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0027-9684%2815%2930559-9

Elucidating the etiology of erectile dysfunction after definitive therapy for prostatic cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0027-9684%2815%2930559-9

Quality of life and satisfaction with outcome among prostate-cancer survivors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0027-9684%2815%2930559-9

Early prostate cancer: clinical decision-making

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0027-9684%2815%2930559-9

Brachytherapy for carcinoma of the prostate: techniques, patient selection, and clinical outcomes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0027-9684%2815%2930559-9

The American Brachytherapy Society recommendations for permanent prostate brachytherapy postimplant dosimetric analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0027-9684%2815%2930559-9

Update on brachytherapy in localized prostate cancer: the importance of dosimetry

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0027-9684%2815%2930559-9

A dose-response study for I-125 prostate implants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0027-9684%2815%2930559-9

Biochemical outcomes after prostate brachytherapy with 5-year minimal follow-up: Importance of patient selection and implant quality

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0027-9684%2815%2930559-9

Dosimetric quantifiers for low-dose-rate prostate brachytherapy: is V(100) superior to D(90)?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0027-9684%2815%2930559-9

Importance of implant dosimetry for patients undergoing prostate brachytherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0027-9684%2815%2930559-9

A descriptive analysis of postimplant dosimetric parameters from Radiation Therapy Oncology Group P0019

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0027-9684%2815%2930559-9

Multi-institutional analysis of long-term outcome for stages T1-T2 prostate cancer treated with permanent seed implantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0027-9684%2815%2930559-9

15-Year biochemical relapse free survival in clinical Stage T1-T3 prostate cancer following combined external beam radiotherapy and brachytherapy; Seattle experience

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0027-9684%2815%2930559-9

Results of a phase II trial of transrectal ultrasound-guided permanent radioactive implantation of the prostate for definitive management of localized adenocarcinoma of the prostate (radiation therapy oncology group 98-05)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0027-9684%2815%2930559-9

Radical prostatectomy, external beam radiotherapy <72 Gy, external beam radiotherapy > or =72 Gy, permanent seed implantation, or combined seeds/external beam radiotherapy for stage T1-T2 prostate cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0027-9684%2815%2930559-9

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0027-9684%2815%2930559-9

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0027-9684%2815%2930559-9

An assessment of quality of life following radical prostatectomy, high dose external beam radiation therapy and brachytherapy iodine implantation as monotherapies for localized prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0027-9684%2815%2930559-9

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0027-9684%2815%2930559-9

Improved biochemical control and clinical disease-free survival with intraoperative versus preoperative preplanning for transperineal interstitial permanent prostate brachytherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0027-9684%2815%2930559-9

Improved conformality and decreased toxicity with intraoperative computer-optimized transperineal ultrasound-guided prostate brachytherapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0027-9684%2815%2930559-9

125I versus 103Pd for low-risk prostate cancer: preliminary PSA outcomes from a prospective randomized multicenter trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0027-9684%2815%2930559-9

Recommendations for permanent prostate brachytherapy with (131)Cs: a consensus report from the Cesium Advisory Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0027-9684%2815%2930559-9

Feasibility of high-dose-rate brachytherapy salvage for local prostate cancer recurrence after radiotherapy: the University of California-San Francisco experience

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0027-9684%2815%2930559-9

A prospective randomized comparison of stranded vs. loose 125I seeds for prostate brachytherapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0027-9684%2815%2930559-9

Loose seeds vs. stranded seeds: a comparison of critical organ dosimetry and acute toxicity in (125)I permanent implant for low-risk prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0027-9684%2815%2930559-9

20 Gy versus 44 Gy supplemental beam radiation with Pd-103 prostate brachytherapy: preliminary biochemical outcomes from a prospective randomized multi-center trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0027-9684%2815%2930559-9

Biochemical relapse-free survival in 400 patients treated with I-125 prostate brachytherapy: the Guildford experience

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0027-9684%2815%2930559-9

Palladium-103 brachytherapy for prostate carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0027-9684%2815%2930559-9

Ten-year biochemical relapse-free survival after external beam radiation and brachytherapy for localized prostate cancer: the Seattle experience

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0027-9684%2815%2930559-9

Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0027-9684%2815%2930559-9

Role of external beam radiotherapy with low-dose-rate brachytherapy in treatment of prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0027-9684%2815%2930559-9

Role of androgen ablation with low-dose-rate brachytherapy in the treatment of prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0027-9684%2815%2930559-9

12-year outcomes following permanent prostate brachytherapy in patients with clinically localized prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0027-9684%2815%2930559-9

Disease-specific survival following the brachytherapy management of prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0027-9684%2815%2930559-9

Relationship between percent positive biopsies and biochemical outcome after permanent interstitial brachytherapy for clinically organ-confined carcinoma of the prostate gland.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0027-9684%2815%2930559-9

10-year disease-free survival rates after simultaneous irradiation for prostate cancer with a focus on calculation methodology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0027-9684%2815%2930559-9

10.1016/S0027-9684(15)30559-9

7 January 2021

Identifiers

DOI

1 reference

22 August 2017

1 reference